CLINICAL CORE

临床核心

• 批准号: 7035626
• 负责人: HARVEY Ira PASS
• 金额: $ 12.47万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7035626
• 关键词: asbestos; biomedical facility; cell line; environment related neoplasm /cancer; gene environment interaction; human tissue; lung; mesothelioma; microarray technology; simian virus 40; tissue /cell culture; tissue /cell preparation; tissue resource /registry

The Clinical Core housed at the Karmanos Cancer Institute is intended to be a resource for the program project as a whole and as a valuable source of biological materials necessary for the completion of the individual projects. The Clinical Core will be responsible for the collection, storage, and distribution of mesothelial cells and tissues, and mesothelioma tumors. The functions of the Clinical Core will be to serve as a resource for mesothelioma tumor tissue both snap frozen and paraffin embedded, and as a resource for asbestos-exposed pleura, lung, or peritoneum which is either snap frozen or paraffin embedded. The CORE will also serve as a resource for already established mesothelioma cell lines as well as an ongoing source of cultured human mesothelial cells from patients at the Karmanos Cancer Institute. New mesothelioma cell lines will be started prospectively from mesothleioma patients having resection. The Core will be responsible for the determining the SV40 status on these human mesothelial tissues, mesothelial cells, mesothelioma tumors and cultured mesothelioma cell lines in order to provide the appropriate reagents to the investigators. Tissue arrays for immunohistochemical validation of data will be constructed from paraffin embedded tumors and provided to the individual investigators. The Clinical Core will also coordinate the performance of asbestos lung content analysis from patients with mesothelioma for correlative data in the individual projects. It is estimated that 60-80 new mesothelioma cases per year will be seen at the Karmanos Cancer Institute during the course of the program project, and it is conservatively estimated that 20-30 of these will be accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor samples will be used in Projects 1 and 3, and cell lines/cultures will be used in projects 2 and 3. By centralizing these services into a Core, the collection, storage, analysis, and distribution of tissues relevant to mesothelioma carcinogenesis will be better managed and coordinated for the entire Program Project.

Karmanos癌症研究所的临床核心旨在成为该计划的资源 整个项目，也是完成的宝贵生物学材料来源 个别项目。临床核心将负责收集，存储和分配 间皮细胞和组织，以及间皮瘤肿瘤。临床核心的功能将是服务 作为间皮瘤肿瘤组织的一种资源，嵌入了冷冻和石蜡，作为一种资源 石棉暴露的胸膜，肺或腹膜是嵌入的捕获或石蜡。核心 还将作为已经建立的间皮瘤细胞系的资源，以及持续的来源 来自Karmanos癌症研究所患者的培养的人间皮细胞。新的间皮瘤细胞 线皮瘤患者的切除术将前瞻性地开始。核心将负责 为了确定这些人间皮组织，间皮细胞，间皮瘤的SV40状态 肿瘤和培养的间皮瘤细胞系为了向研究者提供适当的试剂。 用于数据的免疫组织化学验证的组织阵列将由石蜡嵌入的肿瘤构建 并提供给个人调查员。临床核心还将协调 中皮瘤患者的石棉肺含量分析单个项目中的相关数据。 据估计，每年将在Karmanos癌症研究所看到60-80例新的间皮瘤病例 在计划项目的过程中，保守估计其中20-30将是 作为新鲜/冷冻标本应计。在所有情况下，都可以使用石蜡嵌入的肿瘤。瘤 样品将用于项目1和3，细胞系/培养物将在项目2和3中使用。 将这些服务集中到核心，集合，存储，分析和分布与 在整个程序项目中，间皮瘤致癌作用将得到更好的管理和协调。